PhenomeX Inc.

NasdaqGS:CELL Stock Report

Market Cap: US$99.6m

PhenomeX Valuation

Is CELL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CELL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CELL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CELL?

Key metric: As CELL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CELL. This is calculated by dividing CELL's market cap by their current revenue.
What is CELL's PS Ratio?
PS Ratio1.4x
SalesUS$71.82m
Market CapUS$99.63m

Price to Sales Ratio vs Peers

How does CELL's PS Ratio compare to its peers?

The above table shows the PS ratio for CELL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.1x
CSBR Champions Oncology
1.9x11.3%US$102.8m
HBIO Harvard Bioscience
0.9x5.8%US$92.0m
NOTV Inotiv
0.2x6.0%US$106.1m
AKYA Akoya Biosciences
1.4x8.9%US$123.4m
CELL PhenomeX
1.4x23.4%US$99.6m

Price-To-Sales vs Peers: CELL is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (1.4x).

Price to Sales Ratio vs Industry

How does CELL's PS Ratio compare vs other companies in the US Life Sciences Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x2.4%US$1.73b
ATLN Atlantic International
0.6xn/aUS$256.75m
NOTV Inotiv
0.2x6.0%US$106.14m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
CELL 1.4xIndustry Avg. 3.4xNo. of Companies8PS02.85.68.411.214+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CELL is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is CELL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CELL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio5x

Price-To-Sales vs Fair Ratio: CELL is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/04 07:17
End of Day Share Price 2023/09/29 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PhenomeX Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav GoparajuBerenberg
Mark MassaroBTIG
Tycho PetersonJ.P. Morgan